Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 14/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | FER | P16591 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409232 | 0.85 | FYN (0.62) | TTKFYNSYK | |
| SCHEMBL3470277 | 0.85 | FYN (0.54) | TTKFYNFLT3SYK | |
| SCHEMBL12409240 | 0.83 | FYN (0.53) | TTKFYN | |
| SCHEMBL12409321 | 0.83 | FYN (0.48) | TTKFYNFLT3 | |
| SCHEMBL12409254 | 0.82 | TTK (0.49) | TTKFYN | |
| SCHEMBL12409292 | 0.81 | FYN (0.60) | TTKFYN | |
| SCHEMBL12409252 | 0.80 | ZAP70 (0.48) | TTKFYNPAX8 | |
| SCHEMBL12409242 | 0.79 | TTK (0.56) | TTKFYNFLT3PAX8LCK | |
| SCHEMBL12409235 | 0.79 | PAX8 (0.48) | TTKFYNPAX8RET | |
| SCHEMBL12409284 | 0.78 | QPCT (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | TTK 3239/4885FYN 3511/4885FLT3 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.